title: Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
abstract: Ferritin levels might correlate with disease activity in classical Hodgkin lymphoma (cHL). We analyzed the prognostic significance of the ferritin value at diagnosis in 173 cHL patients treated with ABVD between 2003 and 2013. The 5-year overall survival (OS) and progression-free survival (PFS) probabilities were 80% and 64%, respectively. Patients with ferritin ≥ 350 μg/l [high ferritin group (HF), n = 62] were more likely to have advanced stage disease, B-symptoms and higher International Prognostic Score (IPS) compared with patients with ferritin < 350 μg/l [low ferritin group (LF), n = 111]. The complete remission (CR) rate and 5-year PFS and OS probabilities were lower in HF vs. LF patients (69% vs. 89%, p = 0.025; 40% vs. 78%, p < 0.001; 61% vs. 90%, p = 0.001; respectively). Multivariate analysis revealed that advanced stage (p = 0.001) and ferritin levels ≥ 350 μg/l (p = 0.002) were independent predictors for PFS. In conclusion, the ferritin level at diagnosis is a useful prognostic marker for cHL.
authors: a Hematology Department of Hospital de Cabueñes , Gijon , Spain.
authors: Ruben
authors: R
authors: Fernandez-Alvarez
authors: b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
authors: Ana P
authors: AP
authors: Gonzalez-Rodriguez
authors: a Hematology Department of Hospital de Cabueñes , Gijon , Spain.
authors: M Esther
authors: ME
authors: Gonzalez
authors: a Hematology Department of Hospital de Cabueñes , Gijon , Spain.
authors: Arturo
authors: A
authors: Rubio-Castro
authors: a Hematology Department of Hospital de Cabueñes , Gijon , Spain.
authors: Francisco
authors: F
authors: Dominguez-Iglesias
authors: b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
authors: Jackeline
authors: J
authors: Solano
authors: b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
authors: Eva
authors: E
authors: Alonso-Nogues
authors: a Hematology Department of Hospital de Cabueñes , Gijon , Spain.
authors: Carmen
authors: C
authors: Fernandez-Alvarez
authors: c Hematology Department of Hospital San Agustin , Aviles , Spain.
authors: Yahya
authors: Y
authors: Zanabili
authors: d Hematology Department of Hospital Valle del Nalon , Langreo , Spain.
authors: Jose Manuel
authors: JM
authors: Alonso
authors: b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
authors: Angel Ramirez
authors: AR
authors: Payer
authors: e Hematology Department of Hospital Alvarez Buylla , Mieres , Spain.
authors: Jose Maria
authors: JM
authors: Vicente
authors: c Hematology Department of Hospital San Agustin , Aviles , Spain.
authors: Jesus
authors: J
authors: Medina
authors: f Hematology Department of ICO-Hospital Germans Trias i Pujol , Jose Carreras Research Institute , Badalona , Universitat Autonoma de Barcelona , Spain.
authors: Juan M
authors: JM
authors: Sancho
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D001761:Bleomycin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood*; D006689:Hodgkin Disease / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D011878:Radiotherapy; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D015415:Biomarkers; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D005293:Ferritins
keywords: Biomarker; Hodgkin lymphoma; ferritin; lymphoma; prognosis